Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-13

Clinical Trial Update: Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) [Phase 2]

View source ↗

Summary

Phase 2 study of ertugliflozin in adults with type 2 diabetes and hypertension completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Type 2, Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2017-12-13